ES2871823T3 - Biomarcadores relacionados con la función renal y métodos para utilizarlos - Google Patents
Biomarcadores relacionados con la función renal y métodos para utilizarlos Download PDFInfo
- Publication number
- ES2871823T3 ES2871823T3 ES19176215T ES19176215T ES2871823T3 ES 2871823 T3 ES2871823 T3 ES 2871823T3 ES 19176215 T ES19176215 T ES 19176215T ES 19176215 T ES19176215 T ES 19176215T ES 2871823 T3 ES2871823 T3 ES 2871823T3
- Authority
- ES
- Spain
- Prior art keywords
- subject
- level
- ckd
- acetylalanine
- biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 272
- 230000003907 kidney function Effects 0.000 title claims abstract description 200
- 238000000034 method Methods 0.000 title claims abstract description 87
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 claims abstract description 45
- 239000012472 biological sample Substances 0.000 claims abstract description 26
- 238000013178 mathematical model Methods 0.000 claims abstract description 16
- 230000024924 glomerular filtration Effects 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract 6
- 239000000523 sample Substances 0.000 claims description 56
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 49
- 238000003745 diagnosis Methods 0.000 claims description 33
- 210000002966 serum Anatomy 0.000 claims description 30
- 229940109239 creatinine Drugs 0.000 claims description 25
- PEDXUVCGOLSNLQ-WUJLRWPWSA-N N-acetyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(C)=O PEDXUVCGOLSNLQ-WUJLRWPWSA-N 0.000 claims description 24
- 210000003734 kidney Anatomy 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 20
- 229930185560 Pseudouridine Natural products 0.000 claims description 19
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 19
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 19
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 19
- 210000002700 urine Anatomy 0.000 claims description 19
- 238000005259 measurement Methods 0.000 claims description 18
- 102000009027 Albumins Human genes 0.000 claims description 17
- 108010088751 Albumins Proteins 0.000 claims description 17
- -1 C-glucosyltryptophan Chemical compound 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 14
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 12
- 229960000367 inositol Drugs 0.000 claims description 12
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims description 7
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 claims description 5
- UZTFMUBKZQVKLK-UHFFFAOYSA-N 4-acetamidobutanoic acid Chemical compound CC(=O)NCCCC(O)=O UZTFMUBKZQVKLK-UHFFFAOYSA-N 0.000 claims description 5
- 229920002160 Celluloid Polymers 0.000 claims description 5
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 5
- JPIJQSOTBSSVTP-PWNYCUMCSA-N D-erythronic acid Chemical compound OC[C@@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-PWNYCUMCSA-N 0.000 claims description 5
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 5
- 239000004386 Erythritol Substances 0.000 claims description 5
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 5
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 claims description 5
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 claims description 5
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims description 5
- UNUYMBPXEFMLNW-DWVDDHQFSA-N N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine Chemical compound C1=NC=2C(NC(=O)N[C@@H]([C@H](O)C)C(O)=O)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UNUYMBPXEFMLNW-DWVDDHQFSA-N 0.000 claims description 5
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 5
- 229940009714 erythritol Drugs 0.000 claims description 5
- 235000019414 erythritol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 229940099459 n-acetylmethionine Drugs 0.000 claims description 5
- IHCPDBBYTYJYIL-QVDQXJPCSA-N (R)-2-methylbutyrylcarnitine Chemical compound CCC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IHCPDBBYTYJYIL-QVDQXJPCSA-N 0.000 claims description 4
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 claims description 4
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 claims description 4
- AQTYXAPIHMXAAV-UHFFFAOYSA-N O-methoxycatechol-O-sulphate Chemical compound COC1=CC=CC=C1OS(O)(=O)=O AQTYXAPIHMXAAV-UHFFFAOYSA-N 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- CPXSBHKDEPPWIX-MKWJWUHGSA-N (2S)-2-amino-3-[2-[(3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-1H-indol-3-yl]propanoic acid Chemical compound C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)C1=C(C[C@H](N)C(=O)O)C2=CC=CC=C2N1 CPXSBHKDEPPWIX-MKWJWUHGSA-N 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- HFCPFJNSBPQJDP-UHFFFAOYSA-N O-3-methylglutarylcarnitine Chemical compound [O-]C(=O)CC(C)CC(=O)OC(CC(O)=O)C[N+](C)(C)C HFCPFJNSBPQJDP-UHFFFAOYSA-N 0.000 claims description 3
- XUYANFPPYJSBPU-QMMMGPOBSA-N bisorcic Chemical compound CC(=O)NCCC[C@@H](C(O)=O)NC(C)=O XUYANFPPYJSBPU-QMMMGPOBSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 claims 2
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 claims 2
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 claims 2
- JDTWZSUNGHMMJM-UHFFFAOYSA-N N-acetylisoleucine Chemical compound CCC(C)C(C(O)=O)NC(C)=O JDTWZSUNGHMMJM-UHFFFAOYSA-N 0.000 claims 2
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 claims 1
- FKTXRTPBUWLETL-QMMMGPOBSA-N N-acetyl-3-methyl-L-histidine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CN=CN1C FKTXRTPBUWLETL-QMMMGPOBSA-N 0.000 claims 1
- KBOJOGQFRVVWBH-ZETCQYMHSA-N N-acetyl-L-histidine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CN=CN1 KBOJOGQFRVVWBH-ZETCQYMHSA-N 0.000 claims 1
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 claims 1
- GNMSLDIYJOSUSW-LURJTMIESA-N N-acetyl-L-proline Chemical compound CC(=O)N1CCC[C@H]1C(O)=O GNMSLDIYJOSUSW-LURJTMIESA-N 0.000 claims 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 claims 1
- LJLLAWRMBZNPMO-UHFFFAOYSA-N N-acetyl-beta-alanine Chemical compound CC(=O)NCCC(O)=O LJLLAWRMBZNPMO-UHFFFAOYSA-N 0.000 claims 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 claims 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229940116191 n-acetyltryptophan Drugs 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 description 185
- 239000002207 metabolite Substances 0.000 description 39
- 150000001875 compounds Chemical class 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000006399 behavior Effects 0.000 description 17
- 238000004422 calculation algorithm Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 238000010219 correlation analysis Methods 0.000 description 14
- 230000014759 maintenance of location Effects 0.000 description 13
- 208000009304 Acute Kidney Injury Diseases 0.000 description 12
- 208000033626 Renal failure acute Diseases 0.000 description 12
- 201000011040 acute kidney failure Diseases 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 230000006378 damage Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 9
- 230000001771 impaired effect Effects 0.000 description 9
- 102000012192 Cystatin C Human genes 0.000 description 8
- 108010061642 Cystatin C Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000017667 Chronic Disease Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 206010062237 Renal impairment Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 231100000857 poor renal function Toxicity 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000001790 Welch's t-test Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000028208 end stage renal disease Diseases 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000009592 kidney function test Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000013179 statistical model Methods 0.000 description 3
- HAEVNYBCYZZDFL-MRVPVSSYSA-N succinyl-L-carnitine Chemical compound C[N+](C)(C)C[C@@H](CC([O-])=O)OC(=O)CCC(O)=O HAEVNYBCYZZDFL-MRVPVSSYSA-N 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 235000003563 vegetarian diet Nutrition 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- ACEHWAXOSOTKOB-QMMMGPOBSA-N (2s)-6-amino-2-(2-oxopropylamino)hexanoic acid Chemical compound CC(=O)CN[C@H](C(O)=O)CCCCN ACEHWAXOSOTKOB-QMMMGPOBSA-N 0.000 description 1
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical compound C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- IWPAIFMEXMBEJB-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)-2-hydroxyacetamide Chemical compound COC1=CC(OC)=CC(C(O)C(N)=O)=C1 IWPAIFMEXMBEJB-UHFFFAOYSA-N 0.000 description 1
- QAJHSBCVZSSXCM-UHFFFAOYSA-N 3,8-dihydroxy-4,8-dioxo-3-[1-(trimethylazaniumyl)ethyl]octanoate Chemical compound CC(C(O)(CC([O-])=O)C(CCCC(=O)O)=O)[N+](C)(C)C QAJHSBCVZSSXCM-UHFFFAOYSA-N 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000002665 bowman capsule Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- LBRBNZLTISPFDM-YFKPBYRVSA-N formyl (2S)-2-amino-4-methylsulfanylbutanoate Chemical compound CSCC[C@H](N)C(=O)OC=O LBRBNZLTISPFDM-YFKPBYRVSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000013062 quality control Sample Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822965P | 2013-05-14 | 2013-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2871823T3 true ES2871823T3 (es) | 2021-11-02 |
Family
ID=51898805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19176215T Active ES2871823T3 (es) | 2013-05-14 | 2014-05-13 | Biomarcadores relacionados con la función renal y métodos para utilizarlos |
| ES14797070T Active ES2702123T3 (es) | 2013-05-14 | 2014-05-13 | Biomarcadores relacionados con la función renal y métodos para utilizarlos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14797070T Active ES2702123T3 (es) | 2013-05-14 | 2014-05-13 | Biomarcadores relacionados con la función renal y métodos para utilizarlos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10539575B2 (enExample) |
| EP (3) | EP3546940B1 (enExample) |
| JP (1) | JP6595984B2 (enExample) |
| CN (2) | CN110196335A (enExample) |
| AU (1) | AU2014265669B2 (enExample) |
| BR (1) | BR112015028253A2 (enExample) |
| CA (2) | CA3184836A1 (enExample) |
| ES (2) | ES2871823T3 (enExample) |
| MX (2) | MX365061B (enExample) |
| WO (1) | WO2014186311A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014186311A1 (en) * | 2013-05-14 | 2014-11-20 | Metabolon, Inc. | Biomarkers related to kidney function and methods using the same |
| CN111879948A (zh) | 2013-10-17 | 2020-11-03 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| CA2973116C (en) * | 2015-01-09 | 2023-08-15 | Global Genomics Group, LLC | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease |
| US20180003721A1 (en) * | 2015-01-15 | 2018-01-04 | Joslin Diabetes Center | Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients |
| EP3355914B1 (en) | 2015-09-29 | 2024-03-06 | The General Hospital Corporation | A composition comprising bcg for reducing cholesterol. |
| US20170234874A1 (en) * | 2015-10-07 | 2017-08-17 | Clearbridge Biophotonics Pte Ltd. | Integrated visual morphology and cell protein expression using resonance-light scattering |
| US12057228B1 (en) | 2015-12-30 | 2024-08-06 | Cerner Innovation, Inc. | Predicting newly incident chronic kidney disease |
| ES2891088T3 (es) * | 2016-07-28 | 2022-01-26 | Metabolon Inc | Métodos de diagnóstico, agentes terapéuticos y usos de los mismos |
| EP3552022B1 (en) * | 2016-11-25 | 2021-06-09 | Implexion AB | Metabolic disorders |
| WO2018118630A1 (en) | 2016-12-19 | 2018-06-28 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
| CN108956790A (zh) * | 2017-05-18 | 2018-12-07 | 中国人民解放军第二军医大学第二附属医院 | 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用 |
| CN107132266A (zh) * | 2017-06-21 | 2017-09-05 | 佛山科学技术学院 | 一种基于随机森林的水质分类方法及系统 |
| AU2018313853A1 (en) | 2017-08-08 | 2020-01-02 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| CN107326093B (zh) * | 2017-09-04 | 2020-01-21 | 东南大学 | 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用 |
| CA3077029A1 (en) * | 2017-09-28 | 2019-04-04 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
| EP3740760B1 (en) * | 2018-01-19 | 2023-05-31 | Mars, Incorporated | Biomarkers and classification algorithms for chronic kidney disease in cats |
| WO2020018463A1 (en) * | 2018-07-14 | 2020-01-23 | Mars, Incorporated | Biomarkers and test models for chronic kidney disease |
| JP7205940B2 (ja) * | 2019-02-20 | 2023-01-17 | 株式会社パートナーファーム | 固相反応チップ及びこれを用いた測定方法 |
| CN112305089B (zh) * | 2019-07-26 | 2022-04-29 | 长沙都正生物科技股份有限公司 | 一种慢性肾病诊断生物标记物及其应用 |
| WO2021018774A1 (en) * | 2019-07-26 | 2021-02-04 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Ergothioneine, s-methyl-ergothioneine, and uses thereof |
| CN111487338B (zh) * | 2020-04-16 | 2022-06-10 | 中南大学湘雅二医院 | 一种与肾功能相关的无创生物标记物及其应用 |
| WO2021232211A1 (zh) * | 2020-05-19 | 2021-11-25 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| CN114910587B (zh) * | 2022-05-12 | 2024-03-19 | 军科正源(上海)生物医药科技有限公司 | 一种尿液检测用高效液相-串联质谱分析方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196787A (ja) * | 1989-01-25 | 1990-08-03 | Otsuka Pharmaceut Co Ltd | シュードウリジン誘導体 |
| JPH0661278B2 (ja) * | 1990-09-18 | 1994-08-17 | 旭化成工業株式会社 | ミオイノシトールの高感度定量法および定量用組成物 |
| US5712084A (en) * | 1995-09-08 | 1998-01-27 | Research Corporation Technologies, Inc. | Donor kidney viability test for improved preservation |
| CN101377492B (zh) | 2007-08-29 | 2014-04-23 | 北京九强生物技术股份有限公司 | 胱抑素c测定试剂盒 |
| CA2735590A1 (en) * | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9421330B2 (en) | 2008-11-03 | 2016-08-23 | Bayer Healthcare Llc | Mitigation of contrast-induced nephropathy |
| CA2743253A1 (en) * | 2008-11-22 | 2010-05-27 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20100273207A1 (en) * | 2009-04-24 | 2010-10-28 | Raymond Langley | Methods for Diagnosis of Sepsis and Risk of Death |
| JP5197846B2 (ja) | 2009-04-30 | 2013-05-15 | 紀陽 田仲 | 腎疾患重篤度を判定する方法又は装置若しくはその作動方法 |
| WO2010144336A2 (en) * | 2009-06-08 | 2010-12-16 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
| WO2011027573A1 (ja) * | 2009-09-04 | 2011-03-10 | 国立大学法人東北大学 | ヒトにおける新たな腎疾患マーカー物質 |
| NZ625423A (en) * | 2009-12-20 | 2015-02-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8980548B2 (en) * | 2010-05-19 | 2015-03-17 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| JP5899213B2 (ja) * | 2010-08-06 | 2016-04-06 | マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ | 腎機能不全のバイオマーカーとしてのパールカン |
| JP5916058B2 (ja) * | 2011-08-26 | 2016-05-11 | 国立大学法人東北大学 | 細胞ストレス状態のバイオマーカー |
| CN103814295B (zh) * | 2011-09-14 | 2016-08-24 | 巴斯夫欧洲公司 | 用于评估肾毒性的手段和方法 |
| WO2013048344A1 (en) * | 2011-09-29 | 2013-04-04 | National University Of Singapore | Urinary metabolomic markers for renal insufficiency |
| WO2014186311A1 (en) * | 2013-05-14 | 2014-11-20 | Metabolon, Inc. | Biomarkers related to kidney function and methods using the same |
| ES2891088T3 (es) * | 2016-07-28 | 2022-01-26 | Metabolon Inc | Métodos de diagnóstico, agentes terapéuticos y usos de los mismos |
-
2014
- 2014-05-13 WO PCT/US2014/037762 patent/WO2014186311A1/en not_active Ceased
- 2014-05-13 US US14/889,930 patent/US10539575B2/en active Active
- 2014-05-13 CA CA3184836A patent/CA3184836A1/en active Pending
- 2014-05-13 CN CN201910484069.9A patent/CN110196335A/zh active Pending
- 2014-05-13 EP EP19176215.2A patent/EP3546940B1/en active Active
- 2014-05-13 EP EP14797070.1A patent/EP2997366B1/en active Active
- 2014-05-13 EP EP18183240.3A patent/EP3410115A1/en not_active Withdrawn
- 2014-05-13 ES ES19176215T patent/ES2871823T3/es active Active
- 2014-05-13 JP JP2016514016A patent/JP6595984B2/ja active Active
- 2014-05-13 AU AU2014265669A patent/AU2014265669B2/en active Active
- 2014-05-13 BR BR112015028253A patent/BR112015028253A2/pt not_active Application Discontinuation
- 2014-05-13 CN CN201480027332.7A patent/CN105209909B/zh active Active
- 2014-05-13 MX MX2015015561A patent/MX365061B/es active IP Right Grant
- 2014-05-13 CA CA2911204A patent/CA2911204C/en active Active
- 2014-05-13 ES ES14797070T patent/ES2702123T3/es active Active
- 2014-05-13 MX MX2019005748A patent/MX391220B/es unknown
-
2019
- 2019-12-02 US US16/700,098 patent/US20200103417A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015015561A (es) | 2016-02-05 |
| MX365061B (es) | 2019-05-22 |
| EP2997366B1 (en) | 2018-10-10 |
| US20160116486A1 (en) | 2016-04-28 |
| CN110196335A (zh) | 2019-09-03 |
| ES2702123T3 (es) | 2019-02-27 |
| EP2997366A4 (en) | 2017-04-12 |
| MX2019005748A (es) | 2019-08-12 |
| CA3184836A1 (en) | 2014-11-20 |
| AU2014265669B2 (en) | 2020-05-14 |
| US10539575B2 (en) | 2020-01-21 |
| MX391220B (es) | 2025-03-21 |
| HK1218331A1 (zh) | 2017-02-10 |
| WO2014186311A1 (en) | 2014-11-20 |
| CA2911204C (en) | 2023-03-28 |
| CN105209909A (zh) | 2015-12-30 |
| HK1222905A1 (en) | 2017-07-14 |
| EP3546940A1 (en) | 2019-10-02 |
| US20200103417A1 (en) | 2020-04-02 |
| CA2911204A1 (en) | 2014-11-20 |
| EP3546940B1 (en) | 2021-02-17 |
| AU2014265669A1 (en) | 2015-12-24 |
| BR112015028253A2 (pt) | 2017-07-25 |
| EP3410115A1 (en) | 2018-12-05 |
| EP2997366A1 (en) | 2016-03-23 |
| JP6595984B2 (ja) | 2019-10-23 |
| JP2016520192A (ja) | 2016-07-11 |
| CN105209909B (zh) | 2019-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2871823T3 (es) | Biomarcadores relacionados con la función renal y métodos para utilizarlos | |
| JP6082026B2 (ja) | 肺癌診断用の組成物、方法及びキット | |
| US20200188907A1 (en) | Marker analysis for quality control and disease detection | |
| CN118471335B (zh) | 用于诊断宫颈癌淋巴转移的设备、方法、系统及其应用 | |
| WO2013188333A1 (en) | Biomarkers related to nephrotoxicity and methods using the same | |
| Ress et al. | Reference intervals for venous blood gas measurement in adults | |
| Setoyama et al. | Personality classification enhances blood metabolome analysis and biotyping for major depressive disorders: two-species investigation | |
| Petrick et al. | Comparison of maternal venous blood metabolomics collected as dried blood spots, dried blood microsamplers, and plasma for integrative environmental health research | |
| Ladror et al. | Quantification of cotinine in dried blood spots as a biomarker of exposure to tobacco smoke | |
| US20150310169A1 (en) | Metabolic profiling in tissue and serum is indicative of tumor differentiation in prostate cancer | |
| Younes et al. | Performance evaluation of a new fluorescent-based lateral flow immunoassay for quantification of Hemoglobin A1c (HBA1c) in diabetic patients | |
| Seyfinejad et al. | Biomarkers in Exhaled Breath Condensate as Fingerprints of Asthma, Chronic Obstructive Pulmonary Disease and Asthma–Chronic Obstructive Pulmonary Disease Overlap: A Critical Review | |
| Gug et al. | Salivary biomarkers in toxicology: an update narrative | |
| Shankar et al. | Identification of end‐stage renal disease metabolic signatures from human perspiration | |
| HK1218331B (zh) | 与肾功能相关的生物标记及其使用方法 | |
| Nakorn et al. | Untargeted analysis of the plasma metabolome in canine acute pancreatitis | |
| El-Meshad et al. | Iron status in children with acute COVID-19 and paediatric inflammatory multisystem syndrome during infection and after recovery | |
| Petersson | Exploring metabolic and functional changes in stroke patients: insights from a urinary and blood-derived metabolomic study | |
| HK1222905B (en) | Biomarkers related to kidney function and methods using the same | |
| US20160245814A1 (en) | Biomarkers for kidney cancer and methods using the same | |
| CN121027355A (zh) | 用于诊断慢性阻塞性肺疾病的血清学生物标志物 | |
| CN120594840A (zh) | 用于评估羟氯喹治疗IgA肾病疗效的标志物及应用 | |
| Contributed by members of the ISBER Biospecimen Science Working Group | Biorepository proficiency testing for the quality control of biospecimens for the global biobanking community | |
| BR102018074938A2 (pt) | biomarcadores lipídicos, método e kit para prognóstico laboratorial de acidente vascular isquêmico na fase subaguda a partir de plasma sanguíneo | |
| BRPI1105603B1 (pt) | Método de identificação de perfis de metabólitos para determinação da resistência de células cancerosas de leucemia linfoide aguda (lla) à quimioterapia |